Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CON, LIC, TRI

PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target


TOKYO, Nov. 28, 2023 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company ("Lilly").

Under the agreement, PRISM and Lilly will collaborate to discover small molecule inhibitors of a PPI target selected by Lilly utilizing PRISM's proprietary PepMetics® technology. Lilly has the option to add up to two more targets to the collaboration and is responsible for the clinical development and commercialization of resulting products. PRISM will receive upfront payments and is eligible to receive up to $660 million in pre-clinical, clinical and commercial development milestones payments, as well as royalties on product sales.

"We are very excited to enter into this collaboration with Lilly as we apply our technology to expand the field of drug discovery into a novel approach to drug the PPI targets," said Dai Takehara, President and Chief Executive Officer of PRISM Biolab. "Our PepMetics® technology holds promise to change the current paradigm in drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules. This collaboration with Lilly, an innovative global pharma company, could help us realize this vision and expand the field of druggable targets for the benefit of patients."

About PRISM BioLab

PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics® are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics® technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics.

PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai and Ohara Pharmaceuticals are in clinical development for cancer and liver disease, respectively.

www.prismbiolab.com

Media Contact: Yuka Shimashita, y.shimashita@prismbiolab.jp

SOURCE PRISM BioLab Co., Ltd.


These press releases may also interest you

at 17:00
zkLink, the leading zero-knowledge(ZK) Layer 3 infrastructure provider, today announced the launch of zkLink Nova, the industry's first aggregated Layer 3 zkEVM rollup network, based on zkSync's ZK Stack and zkLink Nexus. zkLink Nova unifies...

at 15:07
The secondary market for luxury watches is worth $25 billion. Analysts say it will outstrip the primary market by 2032. However, the WatchCharts Overall Index is down almost 40% since its March 2022 peak.While losses may have slowed in recent months,...

at 15:00
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of InMode Ltd. between June 4, 2021 and October 12, 2023, both dates inclusive (the "Class Period"), of the important April 15, 2024 lead plaintiff deadline....

at 13:49
We, Prime Minister of Canada Justin Trudeau and President of the Council of Ministers of Italy Giorgia Meloni, met today in Toronto, Ontario, to reaffirm the profound friendship and the shared values that bind Canada and Italy and to discuss our...

at 12:01
Sure, Phil Zamloot's team can make you a great trade show booth at a really good price. But that's not what makes him and his company, Metro Exhibits, so successful....

at 12:00
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Inari Medical, Inc. resulting from allegations that Inari Medical may have issued materially misleading...



News published on and distributed by: